The multinational Phase 3 B-LONG study demonstrated the prolonged half-life of recombinant factor IX Fc fusion protein (rFIXFc) versus native recombinant factor IX (rFIX), and the safety and efficacy of rFIXFc for treatment of bleeding and routine prophylaxis in subjects with hemophilia B. This post hoc subgroup analysis of B-LONG evaluated the safety, efficacy, and pharmacokinetics of rFIXFc in Japanese subjects. Previously treated males with moderately severe to severe hemophilia B (endogenous FIX
Introduction
Hemophilia B is an X-linked hereditary bleeding disorder resulting from deficiency of functional coagulation factor IX (FIX). 1 Hemophilia B affects approximately 1 in every 50,000 live births and is found in all racial and ethnic groups. [1] [2] [3] It is characterized by recurrent, spontaneous bleeding episodes, primarily involving the joints and muscles, which may lead to joint destruction and disabling arthritis. 4 Prophylactic FIX replacement is considered the preferred treatment regimen for patients with hemophilia, 5 as it has demonstrated improvement in long-term outcomes (eg, reduced rates of bleeding and arthropathy) compared with the episodic use of FIX to control acute bleeding events. [6] [7] [8] [9] However, the half-life of conventional FIX products necessitates intravenous infusions approximately 2 times weekly, which limits acceptance of and adherence to prophylaxis. 6, 10, 11 Recombinant factor IX Fc fusion protein (rFIXFc) was developed to have a prolonged half-life compared with conventional FIX products. rFIXFc is composed of a single molecule of recombinant FIX (rFIX) covalently fused to the Fc domain of human immunoglobulin G1 (IgG 1 ), which binds to the neonatal Fc receptor (FcRn) to prolong its half-life. 12 A prolonged half-life has been demonstrated for rFIXFc in both Phase 1/2a and Phase 3 (B-LONG) global studies, with a reported geometric mean terminal half-life of 82.1 hours in the Phase 3 B-LONG study. 13 In both clinical studies, rFIXFc was well tolerated, and no inhibitors (neutralizing antibodies) were reported in previously treated subjects. In the Phase 3 B-LONG study, rFIXFc prophylaxis was associated with low annualized bleeding rates (ABRs) when dosed every 1 to 2 weeks. 11, [13] [14] [15] Long-acting coagulation factors, such as rFIXFc, have the potential to reduce the frequency of infusions required for prophylactic therapy, and consequently, to improve adherence to these regimens, 16 which may lead to decreased bleeding episodes and improved patient outcomes. 17 Currently, rFIXFc is the only long-acting FIX product approved in Japan. 15 The objective of this post hoc analysis was to confirm that the safety, efficacy, and pharmacokinetics of rFIXFc in Japanese subjects enrolled in the multinational Phase 3 B-LONG study were comparable to those obtained for non-Japanese subjects in B-LONG.
Materials and Methods

Subjects
The study design of B-LONG has previously been described in detail. 13 Briefly, subjects were males ≥12 years of age with moderately severe to severe hemophilia B (≤2 IU/dL [2%] endogenous FIX) who had previously been treated either prophylactically, or had been treated episodically with a history of ≥8 bleeding events in the year prior to enrollment. Subjects with a history of inhibitors were excluded. The study was conducted in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice, and registered with ClinicalTrials.gov (NCT01027364). All subjects (or their guardians) gave written informed consent.
Study Design
Subjects were assigned to 1 of 4 treatment groups:
weekly prophylaxis, individualized interval prophylaxis, episodic treatment, or perioperative management. Subjects in the weekly prophylaxis group received a starting dose of 50 IU/kg weekly, with dose adjustment to maintain FIX trough levels 1 to 3 IU/dL above baseline (or higher if clinically necessary). Subjects in the individualized interval prophylaxis group received a starting dose of 100 IU/kg every 10 days, with interval adjustment to maintain FIX trough levels 1 to 3 IU/dL above baseline (or higher if clinically necessary). Subjects in the episodic treatment group received 20 to 100 IU/kg of rFIXFc as needed for bleeding episodes (dose adjusted for severity of bleeding event). Subjects in the perioperative management group received rFIXFc for perioperative care (subjects in this group could be enrolled from any other study group or as new subjects). Results from the primary analysis of B-LONG, detailed results from the perioperative management group, and a post hoc analysis of subjects switching from conventional to rFIXFc prophylaxis have previously been published. 13, 18, 19 A subgroup of participants in the weekly prophylaxis group underwent sequential pharmacokinetic assessment, during which subjects received a single dose of 50 IU/kg of rFIX (BENEFIX ® ; Pfizer, Philadelphia, PA, USA), followed by a 50 IU/kg dose of rFIXFc (administered after a 120-hour washout period). Standard pharmacokinetic evaluation was completed for all other Japanese and non-Japanese subjects following 50 or 100 IU/kg doses of rFIXFc. Pharmacokinetics were evaluated for up to 96 hours for rFIX and for 240 or 336 hours for rFIXFc, depending on the dose of rFIXFc used (for 1 Japanese subject, pharmacokinetic assessment could only be completed through 168 hours due to the occurrence of a spontaneous bleed on Day 7).
Inhibitor testing was performed at screening, just prior to the first rFIXFc infusion, and at every study visit. Details of inhibitor testing have been published previously. 13 The primary endpoints of B-LONG were ABR, the incidence of adverse events, and the development of inhibitors. Key secondary endpoints included in this subanalysis were pharmacokinetics, rFIXFc dose (weekly prophylaxis group) and dosing interval (individualized interval prophylaxis group), and the dose and number of rFIXFc infusions required to stop a bleeding episode.
Analyses
In this post hoc analysis, descriptive statistics were used to describe efficacy and safety endpoints for Japanese and non-Japanese subjects enrolled in B-LONG; the small sample size prevented statistical comparisons between groups. A noncompartmental pharmacokinetic analysis was performed to characterize baseline rFIXFc pharmacokinetic parameters of Japanese subjects and the non-Japanese subjects in the sequential pharmacokinetic subgroup.
Results
Of the 123 subjects enrolled in the B-LONG study, 6 subjects were Japanese. Of the 6 Japanese subjects, Noncompartmental pharmacokinetic analysis. b All non-Japanese subjects from the sequential pharmacokinetic subgroup who had an evaluable pharmacokinetic profile for baseline rFIXFc. c All Japanese subjects, regardless of their treatment group, with an evaluable pharmacokinetic profile for baseline rFIXFc. 
Treatment of Bleeding Events
A total of 24 bleeding episodes were reported in the 6 Japanese subjects during the study period. Of these, 87.5% (21 bleeding episodes) were resolved with 1 infusion; 95.8% (23 episodes) were resolved with 1 or 2 infusions ( Table 3) in the Japanese subgroup and 97.3% in the overall population). 13, 14 Additionally, a post hoc analysis of data from B-LONG showed that subjects transitioning from prophylaxis with a conventional FIX product to prophylaxis with rFIXFc decreased their infusion frequency and FIX consumption, while experiencing fewer bleeding episodes; moreover, population pharmacokinetic modeling was used to show that these patients have a greater likelihood of maintaining FIX activity above 1 IU/dL while using rFIXFc prophylaxis. 19 Unlike small molecule drugs, whose therapeutic effect and toxicity are mediated through their interaction with enzymes and receptors in target tissues (eg, liver or kidney) and are cleared by metabolism in the liver or filtration via the kidney, Fc fusion proteins are largely confined to the blood and interstitial spaces and cleared by proteolysis or other unknown mechanisms following targetmediated disposition (receptor-mediated endocytosis following drug-receptor binding). 20, 21 Given these mechanistic differences, Fc fusion proteins, like monoclonal antibodies, are less likely than small molecule drugs to be affected by ethnic genotypic variations. 20, 21 Polymorphisms of the FCGRT gene, the gene that encodes the neonatal Fc receptor (FcRn), have been reported in Japanese subjects and in other ethnic groups [21] [22] [23] [24] ; however, no functional differences in FcRn due to these polymorphisms were observed, 22 This analysis is not without limitations. Comparison of Japanese and non-Japanese subjects in B-LONG was not prespecified, and thus this was a post hoc analysis. In addition, the number of Japanese subjects was small, so it was not possible to perform statistical comparisons between groups. However, given the rarity of hemophilia B, this analysis provides useful information in the absence of a larger trial of Japanese subjects. The number of subjects in the current analysis is similar to a previous study evaluating a rFIX product in a Japanese population. 32 Furthermore, the Japanese subjects in this analysis were all on a prophylactic rFIXFc regimen, the majority of subjects were compliant with both the prescribed dose and dosing interval, and all but 1 subject had at least 50 EDs to rFIXFc.
rFIXFc is the first long-acting rFIX product approved for the control and prevention of bleeding episodes in hemophilia B in Japan. 15 Although prophylaxis is considered the preferred therapy for hemophilia patients, a recent survey published in 2015 reported only approximately 44% of individuals with hemophilia B in Japan had received a prophylactic regimen. 33 Other recent Japanese surveys (both published in 2009) have also reported low prophylaxis rates overall (26%; hemophilia A and B combined) and specifically for patients with hemophilia B (16%). 5, 34 Problems associated with prophylaxis initiation in these studies included difficulty with venous access (young children), caregiver unwillingness, and poor adherence. 5 rFIXFc provides a treatment regimen requiring less frequent dosing, which may improve clinical outcomes by increasing adherence rates and adoption of prophylaxis.
Conclusions
This post hoc analysis of B-LONG demonstrated that rFIXFc was safe and efficacious for the control and prevention of bleeding in Japanese subjects. rFIXFc prophylaxis was associated with low ABRs, and most acute bleeds were resolved with 1 rFIXFc infusion. No Japa-nese subject-specific safety concerns were identified. All pharmacokinetic, safety, and efficacy parameters were found to be comparable between Japanese and non-Japanese subjects. Given these results, rFIXFc may allow for less frequent dosing and reduce the treatment burden for hemophilia B compared with conventional rFIX products, ultimately increasing acceptance and compliance to prophylactic treatment.
